Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants

Viruses that specifically replicate in tumor over normal cells offer promising cancer therapies. Oncolytic viruses (OV) not only kill the tumor cells directly; they also promote anti-tumor immunotherapeutic responses. Other major advantages of OVs are that they dose-escalate in tumors and can be genetically engineered to enhance potency and specificity. Unmodified wild type reovirus is a propitious OV currently in phase I–III clinical trials. This review summarizes modifications to reovirus that may improve potency and/or specificity during oncolysis. Classical genetics approaches have revealed reovirus variants with improved adaptation towards tumors or with enhanced ability to establish specific steps of virus replication and cell killing among transformed cells. The recent emergence of a reverse genetics system for reovirus has provided novel strategies to fine-tune reovirus proteins or introduce exogenous genes that could promote oncolytic activity. Over the next decade, these findings are likely to generate better-optimized second-generation reovirus vectors and improve the efficacy of oncolytic reotherapy.

• Publication year

  2015

• Venue

  Viruses

• Publication date

  2015-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/v7122936PMID 26633466PMCID 4690860
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.

  2016cited by this paper
• Newcastle disease virotherapy induces long‐term survival and tumor‐specific immune memory in orthotopic glioma through the induction of immunogenic cell death

  2015cited by this paper
• Reduction of Virion-Associated σ1 Fibers on Oncolytic Reovirus Variants Promotes Adaptation toward Tumorigenic Cells

  2015cited by this paper
• Newly Recruited CD11b+, GR-1+, Ly6Chigh Myeloid Cells Augment Tumor-Associated Immunosuppression Immediately following the Therapeutic Administration of Oncolytic Reovirus

  2015cited by this paper
• Diminished Reovirus Capsid Stability Alters Disease Pathogenesis and Littermate Transmission

  2015cited by this paper
• Junctional adhesion molecule-A, an epithelial-mesenchymal transition inducer, correlates with metastasis and poor prognosis in human nasopharyngeal cancer.

  2015cited by this paper
• Amino acids substitutions in σ1 and μ1 outer capsid proteins of a Vero cell-adapted mammalian orthoreovirus are required for optimal virus binding and disassembly.

  2015cited by this paper
• Junctional adhesion molecule-A promotes proliferation and inhibits apoptosis of gastric cancer.

  2015cited by this paper
• Riboswitch-mediated Attenuation of Transgene Cytotoxicity Increases Adeno-associated Virus Vector Yields in HEK-293 Cells.

  2015cited by this paper
• Tissue-based map of the human proteome

  2015cited by this paper
• Replicating reoviruses with a transgene replacing the codons for the head domain of the viral spike

  2015cited by this paper
• Activity levels of cathepsins B and L in tumor cells are a biomarker for efficacy of reovirus-mediated tumor cell killing

  2015cited by this paper
• Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.

  2014cited by this paper
• Healing after death: antitumor immunity induced by oncolytic adenoviral therapy

  2014cited by this paper
• Oncolytic Virus-Mediated Reversal of Impaired Tumor Antigen Presentation

  2014cited by this paper
• Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense

  2014cited by this paper
• Dysregulation of JAM-A plays an important role in human tumor progression.

  2014cited by this paper
• Artificial riboswitches for gene expression and replication control of DNA and RNA viruses

  2014cited by this paper
• A plasmid-based reverse genetics system for mammalian orthoreoviruses driven by a plasmid-encoded T7 RNA polymerase.

  2014cited by this paper
• Consensus guidelines for the detection of immunogenic cell death

  2014cited by this paper
• High-throughput flow cytometry screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor.

  2014cited by this paper
• Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1PV and Gemcitabine in Pancreatic Cancer

  2014cited by this paper
• The Nogo receptor NgR1 mediates infection by mammalian reovirus.

  2014cited by this paper
• Mammalian orthoreovirus T3D infects U-118 MG cell spheroids independent of junction adhesion molecule-A

  2014cited by this paper
• The sweet spot: defining virus–sialic acid interactions

  2014cited by this paper
• Overexpression of JAM-A in Non-Small Cell Lung Cancer Correlates with Tumor Progression

  2013cited by this paper
• A novel role for junctional adhesion molecule‐A in tumor proliferation: Modulation by an anti‐JAM‐A monoclonal antibody

  2013cited by this paper
• Cytotoxic and immune‐mediated killing of human colorectal cancer by reovirus‐loaded blood and liver mononuclear cells

  2013cited by this paper
• The μ1 72-96 Loop Controls Conformational Transitions during Reovirus Cell Entry

  2013cited by this paper
• Amino acid substitutions in σ1 and μ1 outer capsid proteins are selected during mammalian reovirus adaptation to Vero cells.

  2013cited by this paper
• Reovirus receptors, cell entry, and proapoptotic signaling.

  2013cited by this paper
• Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation.

  2013cited by this paper
• Rewiring cancer cell death to enhance oncolytic viro-immunotherapy

  2013cited by this paper
• Engineering recombinant reoviruses with tandem repeats and a tetravirus 2A-like element for exogenous polypeptide expression

  2013cited by this paper
• Combining Oncolytic HSV-1 with Immunogenic Cell Death-Inducing Drug Mitoxantrone Breaks Cancer Immune Tolerance and Improves Therapeutic Efficacy

  2013cited by this paper
• Isolation of Reovirus T3D Mutants Capable of Infecting Human Tumor Cells Independent of Junction Adhesion Molecule-A

  2012cited by this paper
• Complete fiber structures of complex trimeric autotransporter adhesins conserved in enterobacteria

  2012cited by this paper
• Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma.

  2012cited by this paper
• Addition of exogenous polypeptides on the mammalian reovirus outer capsid using reverse genetics.

  2012cited by this paper
• Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

  2012cited by this paper
• Utilization of Sialylated Glycans as Coreceptors Enhances the Neurovirulence of Serotype 3 Reovirus

  2012cited by this paper
• Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients

  2012cited by this paper
• In Search of Cathepsins: How Reovirus Enters Host Cells

  2012cited by this paper
• The GM2 Glycan Serves as a Functional Coreceptor for Serotype 1 Reovirus

  2012cited by this paper
• Reovirus Variants with Mutations in Genome Segments S1 and L2 Exhibit Enhanced Virion Infectivity and Superior Oncolysis

  2012cited by this paper
• Molecular Determinants of Proteolytic Disassembly of the Reovirus Outer Capsid*

  2012cited by this paper
• Cell Entry-Associated Conformational Changes in Reovirus Particles Are Controlled by Host Protease Activity

  2012cited by this paper
• Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming

  2011cited by this paper
• Oncolytic Virus-initiated Protective Immunity Against Prostate Cancer.

  2011cited by this paper
• Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer.

  2011cited by this paper
• Oncolytic virus-initiated protective immunity against prostate cancer.

  2011cited by this paper
• ICP34.5 Protein of Herpes Simplex Virus Facilitates the Initiation of Protein Translation by Bridging Eukaryotic Initiation Factor 2α (eIF2α) and Protein Phosphatase 1*

  2011cited by this paper
• Crystal Structure of Reovirus Attachment Protein σ1 in Complex with Sialylated Oligosaccharides

  2011cited by this paper
• Impact of Host Proteases on Reovirus Infection in the Respiratory Tract

  2011cited by this paper
• A Single-Amino-Acid Polymorphism in Reovirus Protein μ2 Determines Repression of Interferon Signaling and Modulates Myocarditis

  2011cited by this paper
• Inhibition of TANK Binding Kinase 1 by Herpes Simplex Virus 1 Facilitates Productive Infection

  2011cited by this paper
• Measles virus causes immunogenic cell death in human melanoma

  2011cited by this paper
• Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer

  2011cited by this paper
• Abrogation of Junctional Adhesion Molecule-A Expression Induces Cell Apoptosis and Reduces Breast Cancer Progression

  2011cited by this paper
• A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer

  2010cited by this paper
• REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer

  2010cited by this paper
• Towards a knowledge-based Human Protein Atlas

  2010cited by this paper
• Attenuated reovirus displays oncolysis with reduced host toxicity

  2010cited by this paper
• Intravenous administration of Reolysin®, a live replication competent RNA virus is safe in patients with advanced solid tumors

  2010cited by this paper
• Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers

  2010cited by this paper
• Determinants of Strain-Specific Differences in Efficiency of Reovirus Entry

  2010cited by this paper
• Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signaling.

  2010cited by this paper
• From Touchdown to Transcription: The Reovirus Cell Entry Pathway

  2010cited by this paper
• Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics

  2010cited by this paper
• An improved reverse genetics system for mammalian orthoreoviruses.

  2010cited by this paper
• Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity

  2010cited by this paper
• 3.3 A cryo-EM structure of a nonenveloped virus reveals a priming mechanism for cell entry.

  2010cited by this paper
• Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication

  2009cited by this paper
• Genetic and Pharmacologic Alteration of Cathepsin Expression Influences Reovirus Pathogenesis

  2009cited by this paper
• Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity

  2009cited by this paper
• Activation of an Antiviral Response in Normal but Not Transformed Mouse Cells: a New Determinant of Minute Virus of Mice Oncotropism

  2009cited by this paper
• Reciprocal Human Dendritic Cell–Natural Killer Cell Interactions Induce Antitumor Activity Following Tumor Cell Infection by Oncolytic Reovirus1

  2009cited by this paper
• Junctional adhesion molecule-A is required for hematogenous dissemination of reovirus.

  2009cited by this paper
• A Genecentric Human Protein Atlas for Expression Profiles Based on Antibodies*

  2008cited by this paper
• The immune system--is it relevant to cancer development, progression and treatment?

  2008cited by this paper
• Reovirus μ2 Protein Inhibits Interferon Signaling through a Novel Mechanism Involving Nuclear Accumulation of Interferon Regulatory Factor 9

  2008cited by this paper
• Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

  2008cited by this paper
• Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

  2008cited by this paper
• A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting

  2008cited by this paper
• Transient infection of freshly isolated human colorectal tumor cells by reovirus T3D intermediate subviral particles

  2008cited by this paper
• A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

  2008cited by this paper
• Exploiting synergies between radiation and oncolytic viruses.

  2008cited by this paper
• Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity

  2008cited by this paper
• A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

  2008cited by this paper
• The Human Protein Atlas—a tool for pathology

  2008cited by this paper
• Replacement of Native Adenovirus Receptor-Binding Sites with a New Attachment Moiety Diminishes Hepatic Tropism and Enhances Bioavailability in Mice

  2008cited by this paper
• Structure of Reovirus σ1 in Complex with Its Receptor Junctional Adhesion Molecule-A

  2008cited by this paper
• Conformational changes accompany activation of reovirus RNA-dependent RNA transcription.

  2008cited by this paper
• A positive-feedback mechanism promotes reovirus particle conversion to the intermediate associated with membrane penetration

  2008cited by this paper
• NPXY Motifs in the β1 Integrin Cytoplasmic Tail Are Required for Functional Reovirus Entry

  2008cited by this paper
• Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release.

  2007cited by this paper
• A Mosaic Fiber Adenovirus Serotype 5 Vector Containing Reovirus σ1 and Adenovirus Serotype 3 Knob Fibers Increases Transduction in an Ovarian Cancer Ex vivo System via a Coxsackie and Adenovirus Receptor–Independent Pathway

  2007cited by this paper
• History of oncolytic viruses: genesis to genetic engineering.

  2007cited by this paper
• Features of the mammalian orthoreovirus 3 Dearing l1 single-stranded RNA that direct packaging and serotype restriction.

  2007cited by this paper
• Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells

  2007cited by this paper

• Shaping the Immune Response: Cathepsins in Virus-Dendritic Cell Interactions

  2025cites this paper
• Oncolytic viruses in cancer therapy: Exploring the mechanisms and clinical potential of mammalian and avian reoviruses

  2025cites this paper
• Reovirus oncolysis and the next frontiers for this unique oncoviral immunotherapy.

  2025cites this paper
• Oscillations in a Spatial Oncolytic Virus Model

  2024cites this paper
• Combination Therapy with Secretome of Reovirus-Infected Mesenchymal Stem Cells and Metformin Improves Anticancer Effects of Irinotecan on Colorectal Cancer Cells in vitro

  2024cites this paper
• The reovirus μ2 protein, an enigmatic multifunctional protein with numerous secrets yet to be uncovered.

  2024cites this paper
• Mathematical modelling of reoviruses in cancer cell cultures

  2024cites this paper
• Improved oncolytic activity of a reovirus mutant that displays enhanced virus spread due to reduced cell attachment

  2023cites this paper
• Rational selection of an ideal oncolytic virus to address current limitations in clinical translation.

  2023cites this paper
• Modulation of Reoviral Cytolysis (II): Cellular Stemness

  2023cites this paper
• Modulation of Reoviral Cytolysis (I): Combination Therapeutics

  2023cites this paper
• Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions

  2023cites this paper
• A combination therapy of oncolytic viruses and chimeric antigen receptor T cells: a mathematical model proof-of-concept.

  2022cites this paper
• The μ2 and λ1 Proteins of Mammalian Reovirus Modulate Early Events Leading to Induction of the Interferon Signaling Network

  2022cites this paper
• Genetic Modifications That Expand Oncolytic Virus Potency

  2022cites this paper
• The Reovirus μ2 C-Terminal Loop Inversely Regulates NTPase and Transcription Functions versus Binding to Factory-Forming μNS and Promotes Replication in Tumorigenic Cells

  2021cites this paper
• Mechanisms of Cell Entry by dsRNA Viruses: Insights for Efficient Delivery of dsRNA and Tools for Improved RNAi-Based Pest Control

  2021cites this paper
• Past, Present and Future of Oncolytic Reovirus

  2020cites this paper
• Chorioallantoic Membrane Tumor Model for Evaluating Oncolytic Viruses

  2020cites this paper
• Generation of Genetically RGD σ1-Modified Oncolytic Reovirus That Enhances JAM-A-Independent Infection of Tumor Cells

  2020cites this paper
• Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors

  2020cites this paper
• CSV2018: The 2nd Symposium of the Canadian Society for Virology

  2019cites this paper
• A single mutation in the mammalian orthoreovirus S1 gene is responsible for increased interferon sensitivity in a virus mutant selected in Vero cells.

  2019cites this paper
• Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes

  2019cites this paper
• How Many Mammalian Reovirus Proteins are involved in the Control of the Interferon Response?

  2019cites this paper
• Étude des déterminants de l’induction et de la sensibilité à l’interféron chez le réovirus de mammifères

  2019cites this paper
• Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection

  2018cites this paper
• Multiple proteins differing between laboratory stocks of mammalian orthoreoviruses affect both virus sensitivity to interferon and induction of interferon production during infection.

  2018cites this paper
• Synthesis and Translation of Viral mRNA in Reovirus-Infected Cells: Progress and Remaining Questions

  2018cites this paper
• Current understanding of reovirus oncolysis mechanisms

  2018influential citation
• African Swine Fever Virus NP868R Capping Enzyme Promotes Reovirus Rescue during Reverse Genetics by Promoting Reovirus Protein Expression, Virion Assembly, and RNA Incorporation into Infectious Virions

  2017cites this paper
• Serotype-Specific Killing of Large Cell Carcinoma Cells by Reovirus

  2017cites this paper
• Novel High-throughput Approach for Purification of Infectious Virions

  2016cites this paper
• Deciphering the mechanism(s) which limit reovirus spread in resistant lung and HNSCC cancer cells

  2016cites this paper
• Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus

  2015cites this paper